Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
about
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine ReceptorsPsychometric validation of the Weiss Functional Impairment Rating Scale-Parent Report Form in children and adolescents with attention-deficit/hyperactivity disorderAtomoxetine in patients with ADHD: A clinical and pharmacological review of the onset, trajectory, duration of response and implications for patientsAdd-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit.Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuseHealth state utilities associated with adult attention-deficit/hyperactivity disorder.A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.Efficacy, safety and variability in pharmacotherapy for adults with attention deficit hyperactivity disorder: a meta-analysis and meta-regression in over 9000 patients.Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials.Histaminergic system in brain disorders: lessons from the translational approach and future perspectives.Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients.The histaminergic network in the brain: basic organization and role in disease.Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.New developments around histamine H(3) receptor antagonists/inverse agonists: a patent review (2010 - present).Addressing the lack of studies in attention-deficit/hyperactivity disorder in adults.Controlled Allergen Challenge Facilities and Their Unique Contributions to Allergic Rhinitis Research.Current Investigational Drugs for the Treatment of Attention-Deficit/Hyperactivity Disorder.A network meta-analysis of atomoxetine and osmotic release oral system methylphenidate in the treatment of attention-deficit/hyperactivity disorder in adult patients.Treatments and compositions for attention deficit hyperactivity disorder: a patent review.The Histamine H3 Receptor: Structure, Pharmacology, and Function.Role of the Histamine H3 Receptor in the Central Nervous System.Safety of Treatments for ADHD in Adults: Pairwise and Network Meta-Analyses.Attention deficit hyperactivity disorder, tic disorder, and allergy: is there a link? A nationwide population-based study.Insufficient intake of L-histidine reduces brain histamine and causes anxiety-like behaviors in male mice.Histamine H3 receptor in primary mouse microglia inhibits chemotaxis, phagocytosis, and cytokine secretion.Assessment of the abuse liability of ABT-288, a novel histamine H₃ receptor antagonist.Effects of lisdexamfetamine alone and in combination with s-citalopram on acetylcholine and histamine efflux in the rat pre-frontal cortex and ventral hippocampus.Safety, tolerability and pharmacokinetics of 2-pyridylacetic acid, a major metabolite of betahistine, in a phase 1 dose escalation study in subjects with ADHD.Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).
P2860
Q26827568-7EBD5409-A86D-40DD-BECD-1A2C0EE16841Q27303963-C1847820-E669-4CDC-A813-A98A4063A4CCQ28267079-1DE061DC-9AF9-4F88-AFB9-5B66618CF3C7Q30434804-38F64285-7B04-4FA6-A976-80A9DB2D0C7AQ30462161-89FBC1C3-5D73-4711-BD78-5241E198001BQ33944593-1080C8A0-6CA6-42E2-ABCB-6C35DBA5027BQ34322964-40B62CE2-60BA-448A-84B9-BB2C17AE5F95Q34363257-38DFF6C8-07AF-4D5E-B0AA-FD397E7B0223Q34497314-7AD1CC0F-D607-4F4F-82A9-7A22F05726CAQ34505285-8C45DF68-A74D-4C20-92BE-C6D827C307B2Q34568925-59BFA89D-4A41-45E3-BC7C-B3102C32CC3BQ36792986-B907CC9E-461D-46F5-91FC-DB6EEFDD1BF1Q37637480-A90E88B5-72BD-4915-B6E4-DBCA95C38856Q38115678-C5A435C6-FF95-4559-93C0-CBEE41199085Q38118231-4BC3A5AC-1B3B-46E9-B939-B2F6737C4685Q38153063-502E1D7D-9BB6-44D2-BA0C-E9BBA05D033CQ38205020-117DCEFF-4A9D-4FB4-9BEB-8F0521CA29EAQ38541185-DD646757-BA29-4081-BDC2-03A4A7A4B128Q38712796-B7DA30EB-F582-438D-AF49-1BD22E141069Q38785464-BE78E098-5716-4331-A530-5F250D238FE3Q38823610-193D6683-AE36-46F8-A6F4-73F1A4A45A0DQ38937634-6F11C7B8-80AC-4CEC-8318-B68A76705BCBQ38992604-6E1AE38C-C077-42D7-9604-778D7D1FCFE9Q39213619-C50B7229-42E0-4793-B4BA-5C955F7981DEQ43579915-4D2916E7-4FC9-4405-821C-F702FE20D9A4Q47842191-7E05833B-EA04-46E1-B5D7-39D7AC9696A2Q47989141-A04D7A48-C44F-4617-9B57-1E208B530B1AQ48030646-0A0F9D17-1EE2-4542-855B-803635CCED45Q48190973-A0949D17-D473-4379-8692-28348B5C96A5Q48196961-6830BAD3-89C7-484F-94A7-821ED1F965C7Q50044639-8C55E539-D6F2-4B15-84B8-6A1E08C49289
P2860
Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Randomized clinical study of a ...... eficit hyperactivity disorder.
@en
type
label
Randomized clinical study of a ...... eficit hyperactivity disorder.
@en
prefLabel
Randomized clinical study of a ...... eficit hyperactivity disorder.
@en
P2093
P2860
P1433
P1476
Randomized clinical study of a ...... eficit hyperactivity disorder.
@en
P2093
31001074-ATT2001 Study Investigators
Cristiana Gassmann-Mayer
Ella J Daly
Gahan J Pandina
Kimberly Cooper
Richard H Weisler
P2860
P304
P356
10.2165/11631990-000000000-00000
P577
2012-05-01T00:00:00Z
P6179
1003313575